These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19005160)

  • 1. A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis.
    Tsukahara S; Ikari K; Sato E; Yamanaka H; Hara M; Tomatsu T; Momohara S; Kamatani N
    Ann Rheum Dis; 2008 Dec; 67(12):1791-2. PubMed ID: 19005160
    [No Abstract]   [Full Text] [Related]  

  • 2. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients.
    Morales-Lara MJ; Conesa-Zamora P; García-Simón MS; Pedrero F; Santaclara V; Perez-Guillermo M; Soriano-Navarro E
    Scand J Rheumatol; 2010 Nov; 39(6):518-20. PubMed ID: 20560817
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics.
    Fonseca JE; Carvalho T; Cruz M; Nero P; Sobral M; Mourão AF; Cavaleiro J; Ligeiro D; Abreu I; Carmo-Fonseca M; Branco JC
    Ann Rheum Dis; 2005 May; 64(5):793-4. PubMed ID: 15834068
    [No Abstract]   [Full Text] [Related]  

  • 6. Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis.
    Pinto JA; Rego I; Rodríguez-Gomez M; Cañete JD; Fernandez-López C; Freire M; Fernandez-Sueiro JL; Sanmarti R; Blanco FJ
    J Rheumatol; 2008 Jan; 35(1):177-8. PubMed ID: 18176993
    [No Abstract]   [Full Text] [Related]  

  • 7. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.
    Ranganathan P
    Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.
    van den Bemt BJ; Vos K; den Broeder AA; Blom M; Thurlings RM; Bartelds GM; Stapel SO; Barrera P; Tak PP; Nurmohamed MT; Wolbink GJ
    Ann Rheum Dis; 2009 Aug; 68(8):1368-9. PubMed ID: 19605744
    [No Abstract]   [Full Text] [Related]  

  • 9. Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab.
    Vis M; Wolbink GJ; Lodder MC; Kostense PJ; van de Stadt RJ; de Koning MH; Dijkmans BA; Lems WF
    Arthritis Rheum; 2003 Oct; 48(10):2996-7. PubMed ID: 14558111
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
    Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
    Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
    Odai T; Matsunawa M; Takahashi R; Wakabayashi K; Isozaki T; Yajima N; Miwa Y; Kasama T
    J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the first cycle: retrospective arthritis cohort study.
    Bastian H; Zinke S; Egerer K; Breuer S; Safari F; Burmester GR; Feist E
    J Rheumatol; 2010 May; 37(5):1069-71. PubMed ID: 20439529
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab.
    Armstrong DJ; McCarron MT; Wright GD
    J Rheumatol; 2005 Apr; 32(4):759; author reply 759-60. PubMed ID: 15801041
    [No Abstract]   [Full Text] [Related]  

  • 14. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells.
    Tanino M; Matoba R; Nakamura S; Kameda H; Amano K; Okayama T; Nagasawa H; Suzuki K; Matsubara K; Takeuchi T
    Biochem Biophys Res Commun; 2009 Sep; 387(2):261-5. PubMed ID: 19577537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term treatment of psoriatic arthritis with infliximab.
    Yazdani-Biuki B; Wohlfahrt K; Mulabecirovic A; Mueller T; Hermann J; Graninger WB; Brezinschek HP; Brezinschek RI
    Ann Rheum Dis; 2004 Nov; 63(11):1531-2; author reply 1532. PubMed ID: 15479917
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of rheumatoid meningitis with cyclophosphamide but not infliximab.
    Chou RC; Henson JW; Tian D; Hedley-Whyte ET; Reginato AM
    Ann Rheum Dis; 2006 Aug; 65(8):1114-6. PubMed ID: 16837495
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic study and Fcgamma receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab.
    Nishio S; Yamamoto T; Kaneko K; Tanaka-Matsumoto N; Muraoka S; Kaburaki M; Kusunoki Y; Takagi K; Kawai S
    Mod Rheumatol; 2009; 19(3):329-33. PubMed ID: 19255827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
    Pavelka K; Jarosová K; Suchý D; Senolt L; Chroust K; Dusek L; Vencovský J
    Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab.
    Sakai Y; Sakai S; Otsuka T; Ohno D; Murasawa T; Munakata K; Mizuno K
    Ther Apher Dial; 2009 Jun; 13(3):179-85. PubMed ID: 19527463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.